Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability
IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Subscribe To Our Newsletter & Stay Updated
